Medidata Defines the Future of Life Sciences with Acquisition of SHYFT Analytics

Medical Device Investing

Medidata (NASDAQ:MDSO) today announced that it has entered into a definitive agreement to acquire SHYFT Analytics, bringing the leading platform for clinical development together with the leading platform for commercial and real-world data analytics. As quoted in the press release: The combined platform seamlessly delivers market-leading applications, services, and proven data science capabilities, powered by the largest …

As quoted in the press release:

The combined platform seamlessly delivers market-leading applications, services, and proven data science capabilities, powered by the largest global pool of research data, companies’ own CRM data, 3rd party commercial data, and real-world data sources.
Pharmaceutical, biotech, and medical device companies now have an unprecedented ability to manage and optimize value across the clinical and commercial continuum.
“Together, Medidata and SHYFT are powering customers’ digital transformation with artificial intelligence and real-world analytics to reduce risk, optimize revenue, and ultimately help patients,” said Tarek Sherif, chairman and chief executive officer, Medidata. “Combining our innovative solutions, talented teams and shared values, across both organizations will help life science companies streamline the way they develop products and bring them to market. Getting the right treatment, to the right patient, at the right time is a vision we have long shared with our customers.”

Click here to read the full press release.

Medical Device Investing